<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03236818</url>
  </required_header>
  <id_info>
    <org_study_id>NL41878.029.13</org_study_id>
    <nct_id>NCT03236818</nct_id>
  </id_info>
  <brief_title>Goal Oriented Strategy to Preserve Ejection Fraction Trial</brief_title>
  <acronym>GOSPEL</acronym>
  <official_title>Raising the Bars in the Treatment of Pulmonary Arterial Hypertension: Goal Oriented Strategy to Preserve Ejection Fraction Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective long term feasibility study we examine whether a goal oriented&#xD;
      therapeutic strategy that is able to preserve right ventricular function will result in&#xD;
      improved clinical outcome in patients with pulmonary arterial hypertension. We hypothesize&#xD;
      that right ventricular function can only be preserved when early and aggressive medical&#xD;
      combination therapy not only reduces pulmonary vascular resistance but also pulmonary&#xD;
      pressures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      The current strategy in patients with pulmonary arterial hypertension (PAH)is to improve&#xD;
      exercise capacity which can be achieved by decreasing pulmonary vascular resistance (PVR) and&#xD;
      subsequently increasing cardiac output (CO). Despite this load reduction, a substantial&#xD;
      proportion of patients show progressive right ventricular (RV) dysfunction leading to&#xD;
      clinical worsening and death. A possible explanation is that current therapies show a&#xD;
      relatively modest reduction in PVR, leaving mean pulmonary artery pressure (mPAP) unchanged.&#xD;
      As a consequence RV work, defined as the product of CO and mPAP increases, contributing to&#xD;
      progressive RV dysfunction.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      A goal oriented therapeutic strategy that is able to preserve RV function will result in&#xD;
      improved clinical outcome. RV function can only be preserved when early and aggressive&#xD;
      combination therapy not only reduces PVR but also mPAP.&#xD;
&#xD;
      Study questions:&#xD;
&#xD;
        1. Will a goal oriented strategy to preserve/improve RV function, measured by right&#xD;
           ventricular ejection fraction (RVEF) be effective?&#xD;
&#xD;
        2. Does early and aggressive combination therapy result in improved RV function and&#xD;
           survival during long term follow-up?&#xD;
&#xD;
        3. Does a strategy to preserve RVEF also translate into improvements of other clinically&#xD;
           meaningful parameters?&#xD;
&#xD;
        4. Can RVEF be replaced by more simple measures?&#xD;
&#xD;
        5. Will a goal oriented strategy to improve RVEF also lead to improvement of myocardial&#xD;
           performances and coupling of the RV to its load?&#xD;
&#xD;
      Study design and study population:&#xD;
&#xD;
      In this prospective longitudinal feasibility study, thirty newly diagnosed idiopathic or&#xD;
      heritable PAH patients with New York Heart Association (NYHA) functional class II or III will&#xD;
      be included. Maintenance/improvement of RVEF will be our primary outcome parameter and&#xD;
      therefore cardiac magnetic resonance imaging (CMR) will be performed at baseline and at 4, 8&#xD;
      , 12 and 24 months of follow-up. Six-minute walk testing (6MWT), quality of life&#xD;
      questionnaires and blood sampling (NT-proBNP) will be performed at similar follow-up&#xD;
      intervals. In addition, right heart catheterization (RHC) will be performed at baseline,&#xD;
      after 4, 12 and 24 months of follow-up.&#xD;
&#xD;
      NYHA II patients will start with single agent medical treatment whereas patients with NYHA&#xD;
      III will start on combination therapy (2 treatments). In case of a stable/improved RVEF&#xD;
      during each follow-up measurement (defined as no decrease in RVEF &gt;3% compared to previous&#xD;
      measurement), the treatment strategy will remain unchanged. In case of decreased RVEF &gt;3%,&#xD;
      additional medical therapy will be added. Our hypothesis will prove to be correct when the&#xD;
      additional medical treatment result in improved RVEF during the subsequent follow-up&#xD;
      measurement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in right ventricular ejection fraction</measure>
    <time_frame>4,12, 24 months of follow-up</time_frame>
    <description>The primary endpoint will be change in right ventricular ejection fraction (RVEF) during 2 years of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulmonary vascular resistance</measure>
    <time_frame>4,12, 24 months of follow-up</time_frame>
    <description>Change in pulmonary vascular resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mPAP</measure>
    <time_frame>4,12, 24 months of follow-up</time_frame>
    <description>Change in mPAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output in L/min (Thermodilution method)</measure>
    <time_frame>4,8, 12, 24 months of follow-up</time_frame>
    <description>Change in cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>4,8, 12, 24 months of follow-up</time_frame>
    <description>Change in exercise capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association functional class</measure>
    <time_frame>4,8, 12, 24 months of follow-up</time_frame>
    <description>Change in New York Heart Association functional class</description>
  </secondary_outcome>
  <other_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>4,8, 12, 24 months of follow-up</time_frame>
    <description>Change in NT-proBNP</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life by SF-36 questionnaire</measure>
    <time_frame>4,8, 12, 24 months of follow-up</time_frame>
    <description>Change in Quality of Life</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Upfront combination therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)</intervention_name>
    <description>Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)</description>
    <arm_group_label>Upfront combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Idiopathic or heritable pulmonary arterial hypertension&#xD;
&#xD;
          -  New York Heart Association (NYHA) functional class II or III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other causes of pulmonary arterial hypertension (i.e. collagen vascular disease,&#xD;
             congenital heart disease, chrono-thromboembolic pulmonary hypertension, pulmonary&#xD;
             venous hypertension, left heart failure, hypoxemic lung disease)&#xD;
&#xD;
          -  Pulmonary arterial hypertension targeted therapies before study inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton Vonk Noordegraaf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center, department of pulmonary diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Medical Center, dept Pulmonary diseases</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2017</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>A. Vonk Noordegraaf</investigator_full_name>
    <investigator_title>Clinical Professor, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>right ventricle</keyword>
  <keyword>MRI</keyword>
  <keyword>medical combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

